IPSC

Century Therapeutics, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001850119 Biotech & Drug Discovery

$1.46 −0.12 (−7.59%)

Oct 23 4:00 PM ET · prev $1.58

Market cap

$286.1M

Micro cap

Median target

$4.50

+208% · range $2.00–8.00

Next earnings

Nov 5

in 10 days · EPS est. −$0.11

1 year

+143.3%

from $0.6000 · Oct 27

30 days

−12.6%

from $1.67

52-week range

$0.4650–2.94

−50% from high · low Nov 13

Avg volume 20D

975.4K

Oct 6 spike 2.71M

Short interest

🔒 Subscribers only

Insider net

−$68.1K

0 buyers · 2 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 6 reports · 90 days

Balance 1 bearish · 1 bullish · 4 neutral oldest → newest, height = score

Avg score

·High conf. 4/6 ·Next Earnings date, Nov 5, 2026

Strongest NEUTRAL Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Mar 9 to Mar 12 2 days of insider sells: $45.5K by 2 insiders, avg $2.55
R Mar 12 Century Therapeutics reported full-year 2025 financial results, high…
S May 4 1 insider sell $618.02 at $2.34
A May 27 Mizuho initiates
S Jun 8 to Jun 12 2 days of insider sells: $11.1K by 2 insiders, avg $2.21
S Aug 3 1 insider sell $543.68 at $1.98
S Sep 8 to Sep 14 2 days of insider sells: $9.8K by 2 insiders, avg $1.95
E Oct 2 FDA: Century Therapeutics' CNTY-813 Demonstrates Continued Adva…

Signal stack

Where each data set points today.

InsidersBEARISH

2 insiders sold $68.1K.
InstitutionsBULLISH

Q2 2026: 17 added (0 new), 4 trimmed or exited.
EstimatesRISING

Current-quarter EPS estimate −$0.123 → −$0.110 over 90 days. 1 up, 1 down in 30 days.
TrendDOWNTREND

18% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	DOUBLED	8,091,768	$19.8M
Woodline Partners LP	ADD	4,257,530	$10.4M
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	2,979,529	$7.3M
STATE STREET CORP	DOUBLED	1,843,154	$4.5M
NORTHERN TRUST CORP	DOUBLED	1,593,944	$3.9M
RENAISSANCE TECHNOLOGIES LLC	ADD	1,257,700	$3.1M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	DOUBLED	378,867	$928.2K
Bank of New York Mellon Corp	DOUBLED	299,014	$732.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026

12-month targets · 4 analysts

$1.46 $2.00 $4.50 $8.00

Price is below the lowest target. Median implies +208%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
May 27, 2026	Mizuho INITIATE	INITIATE	Outperform

Insider ledger

Form 4

bought · 0 insiders

$68.1K

sold · 2 insiders

Date	Insider	Type	Value
Sep 14, 2026	Carr Douglas SVP Finance & Operations	SELL	$3.2K
Sep 14, 2026	Russotti Gregory See Remarks	SELL	$5.0K
Sep 11, 2026	Pfeiffenberger Brent President and CEO	TAX W/H	$26.9K
Sep 9, 2026	Truitt Joseph Director	AWARD	148,000 sh
Sep 8, 2026	Carr Douglas SVP Finance & Operations	SELL	$520.70
Sep 8, 2026	Russotti Gregory See Remarks	SELL	$1.1K
Sep 4, 2026	Pfeiffenberger Brent President and CEO	TAX W/H	$976.93
Aug 14, 2026	Pfeiffenberger Brent President and CEO	TAX W/H	$59.9K

Earnings setup

Estimates

Nov 5

reports in 10 days

−$0.11

EPS estimate, this quarter

+11%

estimate change, 90 days

1↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.123

90d

−$0.123

60d

−$0.110

30d

−$0.110

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.11	-$0.12–-$0.08	+0.0%	$0.00
Next Q	-$0.12	-$0.14–-$0.08	+0.0%	$0.00
Current FY	-$0.47	-$0.52–-$0.37	-3.7%	$0.00
Next FY	-$0.45	-$0.55–-$0.28	+0.6%	$0.00